Zevra Therapeutics Inc (ZVRA)
8.58
+0.18
(+2.14%)
USD |
NASDAQ |
Nov 04, 13:09
Zevra Therapeutics Total Assets (Quarterly): 144.41M for June 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 144.41M |
March 31, 2024 | 151.28M |
December 31, 2023 | 172.33M |
September 30, 2023 | 138.98M |
June 30, 2023 | 105.52M |
March 31, 2023 | 106.60M |
December 31, 2022 | 115.34M |
September 30, 2022 | 119.55M |
June 30, 2022 | 124.26M |
March 31, 2022 | 125.71M |
December 31, 2021 | 132.94M |
September 30, 2021 | 137.19M |
June 30, 2021 | 138.80M |
March 31, 2021 | 90.44M |
December 31, 2020 | 11.21M |
September 30, 2020 | 11.20M |
June 30, 2020 | 12.33M |
March 31, 2020 | 8.885M |
December 31, 2019 | 10.51M |
September 30, 2019 | 12.89M |
Date | Value |
---|---|
June 30, 2019 | 13.01M |
March 31, 2019 | 19.87M |
December 31, 2018 | 26.75M |
September 30, 2018 | 18.74M |
June 30, 2018 | 34.00M |
March 31, 2018 | 42.65M |
December 31, 2017 | 52.46M |
September 30, 2017 | 59.31M |
June 30, 2017 | 69.05M |
March 31, 2017 | 75.64M |
December 31, 2016 | 84.89M |
September 30, 2016 | 94.54M |
June 30, 2016 | 104.63M |
March 31, 2016 | 111.94M |
December 31, 2015 | 54.59M |
September 30, 2015 | 61.42M |
June 30, 2015 | 66.54M |
March 31, 2015 | 14.12M |
December 31, 2014 | 13.71M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
8.885M
Minimum
Mar 2020
172.33M
Maximum
Dec 2023
97.76M
Average
119.55M
Median
Sep 2022
Total Assets (Quarterly) Benchmarks
Vanda Pharmaceuticals Inc | 651.37M |
BioCardia Inc | 2.89M |
Xeris Biopharma Holdings Inc | 331.73M |
Crinetics Pharmaceuticals Inc | 935.54M |
Instil Bio Inc | 294.32M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 111.93M |
Shareholders Equity (Quarterly) | 32.48M |
Debt to Equity Ratio | 1.796 |
Current Ratio | 2.000 |
Net Debt Paydown Yield | -4.41% |